About NGIDX
NGIDX is a Healthcare company based in Gurugram (India) founded in 2015. It operates as an in-vitro diagnostics products and services in healthcare. Its Indian entity Nextgen In-Vitro Diagnostics Private Limited reported revenue of ₹1.87 Cr. NGIDX offers products and services including Clinical Chemistry Kits and RT-PCR Kits. Its focus areas include Biotechnology, In-Vitro Diagnostics, Diagnostic Kits and Medical Devices.
Company details
NGIVD is known for delivering in-vitro diagnostic products that emphasize global quality while incorporating local roots in India. Products such as clinical chemistry kits, rapid tests, ELISA kits, and nucleic acid purification kits are developed through innovation and indigenization efforts. Support from grants by BIRAC and accreditation from USISTEF ensures high standards in diagnostics. The companys focus on accurate, affordable, and accessible solutions is evident in its RD and manufacturing processes, contributing to strengthened healthcare across regions.
- Headquarters Gurugram, India
- SectorsHealthcare
- Email••••••••
- Social LinkedIn Instagram
- Legal Name Nextgen In-Vitro Diagnostics Private Limited
- Date of Incorporation 24 Apr, 2015
- Jurisdiction New Delhi, Delhi, India
- Annual Revenue₹1.87 Cr
FY 2024 · +70% YoY
- Net Loss-₹5.85 Cr
FY 2024 · -313% margin
- EBITDA-₹5.09 Cr
FY 2024 · -272% margin
Associated legal entities of NGIDX
NGIDX operates through Nextgen In-Vitro Diagnostics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Nextgen In-Vitro Diagnostics Private Limited CIN U33110DL2015PTC279481 | Active | 24 Apr 2015 | New Delhi, Delhi | ₹1.9 Cr | – | 4 | View details |
Products & Services of NGIDX
NGIDX offers a comprehensive portfolio of products and services, including Clinical Chemistry Kits and RT-PCR Kits.
Reagents and assays are provided for the quantitative analysis of biochemical markers in bodily fluids.
Kits are designed for the accurate detection and quantification of DNA or RNA targets with high sensitivity.
Board of directors of Nextgen In-Vitro Diagnostics Private Limited (NGIDX)
Nextgen In-Vitro Diagnostics Private Limited is the primary company behind NGIDX. The board of Nextgen In-Vitro Diagnostics Private Limited currently have 4 directors; the longest-serving is Varun Chopra, appointed in 2015. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Varun Chopra DIN 01044311 | Director | 24 Apr 2015 | 11 yrs 5 mo | Nextgen In-Vitro Diagnostics Private Limited |
| Sushil Mehta DIN 01010831 | Director | 12 Oct 2016 | 10 yrs | Nextgen In-Vitro Diagnostics Private Limited |
| Ashok Kumar Jain DIN 05332592 | Director | 02 Mar 2020 | 6 yrs 7 mo | Nextgen In-Vitro Diagnostics Private Limited |
| Devashish Ohri DIN 03266071 | Managing Director | 12 Aug 2024 | 2 yrs 2 mo | Nextgen In-Vitro Diagnostics Private Limited |
Financials of NGIDX
Figures of Nextgen In-Vitro Diagnostics Private Limited, the primary company behind NGIDX, for FY 2024. Revenue was ₹1.87 Cr (+70% year on year). Net loss was -₹5.85 Cr (-313% margin). EBITDA was -₹5.09 Cr (-272% margin). Revenue has grown at a compounded annual rate of +59% over three years and +48% over five years.
- ₹1.87 CrRevenue · FY 2024 · +70% YoY
- -₹5.85 CrNet loss · -313% margin
- -₹5.09 CrEBITDA · -272% margin
- ₹2.04 CrPaid-up capital
- +59%Revenue CAGR, 3 years
- +48%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Nextgen In-Vitro Diagnostics Private Limited are on its company page.
Detailed financial statements for NGIDX
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Top companies in Diagnostics & Lab Tech
10 companies that operate in the same segment as NGIDX (Diagnostics & Lab Tech), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | Basel, Basel-stadt, Switzerland | – | USD 77.61 B | 103,250 | |
At-home health tests for biomarkers, nutrition, and hormone analysis. | 2014 | Austin, Texas, United States | USD 330 M | – | 336 | |
Point-of-care and laboratory blood analyzers are developed by EKF. | 1990 | Penarth, Wales, United Kingdom | USD 178.63 K | USD 69.43 M | 303 | |
Blood testing services are offered using finger-prick microsamples. | 2017 | Austin, Texas, United States | USD 37.7 M | – | – | |
Manufactures clinical diagnostic test kits | 1971 | Irvine, California, United States | – | USD 4.45 M | 54 | |
Biomarker-based diagnostic solutions for cancer and cardiovascular diseases are developed. | 2002 | Hennigsdorf, Brandenburg, Germany | USD 36.14 M | – | – | |
Diagnostic instrumentation and assays | 1987 | Puteaux, Hauts-de-seine, France | – | – | – | |
Manufacturer of Laboratory equipment | 1955 | Norwood, Massachusetts, United States | – | – | – | |
Cloud based diagnostics platform for point of care diagnosing | 2014 | Waltham, Massachusetts, United States | USD 703.91 M | USD 115.02 K | 9 | |
Diagnostics technology for infectious diseases and health monitoring is provided. | 2012 | Hong Kong, China | USD 34 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NGIDX
NGIDX was founded in 2015.
NGIDX is headquartered in Gurugram, India. It is registered at Gurugram, Haryana, India.
The primary company behind NGIDX, Nextgen In-Vitro Diagnostics Private Limited, reported revenue of ₹1.87 Cr for FY 2024, up 70% year on year.
NGIVD is known for delivering in-vitro diagnostic products that emphasize global quality while incorporating local roots in India. Products such as clinical chemistry kits, rapid tests, ELISA kits, and nucleic acid purification kits are developed through innovation and indigenization efforts. Support from grants by BIRAC and accreditation from USISTEF ensures high standards in diagnostics. The companys focus on accurate, affordable, and accessible solutions is evident in its RD and manufacturing processes, contributing to strengthened healthcare across regions.
NGIDX offers Clinical Chemistry Kits and RT-PCR Kits.
NGIDX operates through Nextgen In-Vitro Diagnostics Private Limited.
The legal entities of NGIDX currently have 4 directors, including Varun Chopra, Sushil Mehta, Ashok Kumar Jain and others.